TABLE 1.
Demographics and clinical characteristics in different fractionations of NSCLC patients.
| Variables | Total (N = 22) | 3.7Gy*8F (n = 5) | 4.6Gy*6F (n = 6) | 6.2Gy*4F (n = 6) | 10Gy*2F (n = 5) |
|---|---|---|---|---|---|
| Age | — | — | — | — | — |
| < 65 | 12 | 2 | 5 | 3 | 2 |
| ≥65 | 10 | 3 | 1 | 3 | 3 |
| Sex | — | — | — | — | — |
| Male | 14 | 4 | 2 | 4 | 4 |
| Female | 8 | 1 | 4 | 2 | 1 |
| Smoking | — | — | — | — | — |
| Yes | 14 | 4 | 3 | 4 | 3 |
| No | 8 | 1 | 3 | 2 | 2 |
| Pathology | — | — | — | — | — |
| ADC | 14 | 2 | 4 | 5 | 3 |
| SCC | 8 | 3 | 2 | 1 | 2 |
| T stage | — | — | — | — | — |
| T1 | 1 | 0 | 0 | 1 | 0 |
| T2 | 4 | 1 | 0 | 1 | 2 |
| T3 | 4 | 2 | 2 | 0 | 0 |
| T4 | 13 | 2 | 4 | 4 | 3 |
| N stage | — | — | — | — | — |
| N0 | 1 | 0 | 0 | 0 | 1 |
| N1 | 1 | 0 | 1 | 0 | 0 |
| N2 | 6 | 1 | 0 | 4 | 1 |
| N3 | 14 | 4 | 5 | 2 | 3 |
| M stage | — | — | — | — | — |
| M0 | 0 | 0 | 0 | 0 | 0 |
| M1 | 22 | 5 | 6 | 6 | 5 |
| Concurrent chemotherapy | — | — | — | — | — |
| Yes | 6 | 2 | 1 | 2 | 1 |
| No | 16 | 3 | 5 | 4 | 4 |
| Concurrent immunotherapy | — | — | — | — | — |
| Yes | 15 | 3 | 4 | 4 | 4 |
| Pembrolizumab | 3 | 2 | 0 | 0 | 1 |
| Nivolumab | 1 | 1 | 0 | 0 | 0 |
| Atezolizumab | 1 | 0 | 1 | 0 | 0 |
| Tislelizumab | 2 | 0 | 1 | 1 | 0 |
| Toripalimab | 4 | 0 | 1 | 1 | 2 |
| Camrelizumab | 3 | 0 | 0 | 2 | 1 |
| Sintilimab | 1 | 0 | 1 | 0 | 0 |
| No | 7 | 2 | 2 | 2 | 1 |
| Target gene mutation | — | — | — | — | — |
| Yes | 7 | 0 | 2 | 3 | 2 |
| EGFR | 4 | 0 | 1 | 1 | 2 |
| ALK | 1 | 0 | 1 | 0 | 0 |
| KRAS | 1 | 0 | 0 | 1 | 0 |
| BRAF | 1 | 0 | 0 | 1 | 0 |
| No | 15 | 5 | 4 | 3 | 3 |
ADC, adenocarcinoma; SCC, squamous cell carcinoma.